Article Information
History
- April 23, 2020.
Article Versions
- Version 1 (April 21, 2020 - 02:30).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Joseph Magagnoli, M.S.1,2,*,
- Siddharth Narendran, M.D.4,5,*,
- Felipe Pereira, M.D.4,5,*,
- Tammy Cummings, Ph.D.1,
- James W. Hardin, Ph.D.3,
- S. Scott Sutton, Pharm.D.1,2,† and
- Jayakrishna Ambati, M.D.4,5,6,7,†
- 1Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina, USA
- 2Department of Clinical Pharmacy & Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA
- 3Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, South Carolina, USA
- 4Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, Virginia, USA
- 5Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, Virginia, USA
- 6Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA
- 7Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA
- ↵†Correspondence should be addressed to Dr. J. Ambati at ja9qr{at}virginia.edu or Dr. S.S. Sutton at sutton{at}cop.sc.edu.
↵* Mr. Magagnoli, Dr. Narendran, and Dr. Pereira contributed equally to this article
Posted April 23, 2020.
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
